Overview
On 26 February 2019, orphan designation (EU/3/19/2140) was granted by the European Commission to Artemida Pharma Europe Limited, Ireland, for humanised IGg1 monoclonal antibody targeting human transferrin receptor conjugated to human iduronate-2-sulfatase (also known as JR-141) for the treatment of mucopolysaccharidosis type II (Hunter’s syndrome).
Key facts
Active substance |
Humanised IGg1 monoclonal antibody targeting human transferrin receptor conjugated to human iduronate-2-sulfatase
|
Intended use |
Treatment of mucopolysaccharidosis type II (Hunter's syndrome)
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/19/2140
|
Date of designation |
26/02/2019
|
Sponsor |
Artemida Pharma Europe Limited
|
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: